Comment on: Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
- 187 Downloads
To the Editor,
We have read with great interest the article by Franceschi et al. on ‘‘Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?’’ recently published in the ‘‘CLINICAL STUDY” section of the journal .
The authors have performed a retrospective analysis on 43 adult average-risk medulloblastoma patients. One of the main objectives of this analysis was to investigate the outcome of patients with regard of postoperative treatment (CSI alone versus CSI and chemotherapy). Some key findings of the publication and the treatment flow chart are shown in Fig. 1.
KeywordsOverall Survival Medulloblastoma Complete Staging Medulloblastoma Patient Professional Outcome
- 1.Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, Danieli D, Ghimenton C, Gardiman MP, Sturiale C, Poggi R, Mascarin M, Balestrini D, Masotto B, Brandes AA (2016) Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neurooncol. doi: 10.1007/s11060-016-2097-x Google Scholar
- 3.Friedrich C, von Bueren AO, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Hau P, Deinlein F, Kuehl J, Kortmann RD, Rutkowski S (2013) Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur J Cancer 49:893–903CrossRefPubMedGoogle Scholar